Richard Greil

Q: What Schools Are Affiliated With Richard Greil

Richard Greil is affiliated with the following schools: University of California, Los Angeles, Paracelsus Medical University, University of Salzburg, Masaryk University, University of Manchester, Karolinska Institute, Medical University of Graz, University of Innsbruck, Medical University of Vienna, Normandy University Group, University of Cologne, University of Pavia

Richard Greil's AcademicInfluence.com Rankings

Richard Greil

Philosophy

#5855

World Rank

#8775

Historical Rank

Logic

#3065

World Rank

#4170

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Richard Greil's Degrees

Doctorate Medicine Medical University of Vienna
PhD Medical Sciences Medical University of Vienna

Why Is Richard Greil Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard Greil's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019) (1244)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. (2013) (980)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial (2005) (874)
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. (2010) (779)
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. (2009) (622)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) (584)
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (2011) (582)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial (2012) (507)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer (2009) (499)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. (2011) (440)
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. (2009) (438)
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. (2009) (425)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial (2015) (405)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. (2019) (386)
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. (2010) (374)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. (2008) (339)
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. (2014) (315)
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. (2013) (305)
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients (2013) (284)
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. (2007) (280)
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. (2007) (273)
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. (2015) (265)
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. (2012) (263)
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. (2012) (244)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group (2017) (243)
Polyacetylenes from the Apiaceae vegetables carrot, celery, fennel, parsley, and parsnip and their cytotoxic activities. (2005) (224)
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. (2013) (222)
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. (1995) (218)
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. (2009) (217)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. (2019) (205)
Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. (1999) (202)
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. (2011) (200)
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. (1997) (194)
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer (2012) (191)
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. (2020) (191)
Resveratrol, a tumor‐suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl‐2 (2001) (179)
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer (2014) (177)
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. (2015) (175)
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site (2016) (172)
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial (2021) (168)
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial (2021) (168)
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). (2013) (164)
The impact of hemoglobin levels on fatigue and quality of life in cancer patients. (2002) (159)
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases (2011) (154)
Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells (2000) (153)
Molecular and cellular mechanisms of CLL: novel therapeutic approaches (2009) (152)
Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. (1997) (146)
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial (2015) (136)
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. (2017) (135)
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. (2013) (133)
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. (2015) (133)
Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a) (2005) (132)
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (132)
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. (2000) (128)
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. (2010) (128)
KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2018) (128)
Normative data for functional assessment of cancer therapy General scale and its use for the interpretation of quality of life scores in cancer survivors (2004) (121)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer (2019) (120)
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphoma (2010) (116)
Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. (1998) (114)
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. (2010) (111)
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2019) (111)
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. (2010) (109)
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. (2019) (108)
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. (2001) (108)
AID/APOBEC deaminases and cancer (2015) (107)
CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8 (2012) (107)
Fatty acids trigger mitochondrion-dependent necrosis (2010) (106)
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. (2021) (105)
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. (2015) (104)
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. (2021) (101)
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response (2012) (99)
Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin lymphomas and leukaemias: possible influence on growth pattern and leukaemic behaviour. (1989) (96)
Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. (2015) (96)
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. (2013) (93)
Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy (2008) (91)
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group (2014) (91)
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. (2014) (91)
Leg ulcers associated with long-term hydroxyurea therapy. (1998) (90)
Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr (2004) (90)
Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. (2009) (89)
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. (2013) (89)
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. (2008) (89)
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. (2016) (88)
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. (2007) (87)
Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL (2011) (86)
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. (2012) (86)
Up-Regulation of Functional Chemokine Receptor CCR3 in Human Renal Cell Carcinoma (2005) (86)
P81 Benefits of switching postmenopausal women withhormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial (2005) (85)
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer (2007) (84)
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. (2013) (84)
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. (2013) (81)
PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. (2009) (78)
Transendothelial Migration of Myeloma Cells Is Increased by Tumor Necrosis Factor (TNF)-α via TNF Receptor 2 and Autocrine Up-Regulation of MCP-1 (2004) (76)
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer (2011) (76)
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. (2008) (76)
Quality of life measurement in oncology--a matter of the assessment instrument? (2001) (74)
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. (2017) (72)
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. (2016) (72)
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial (2015) (71)
A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer (2018) (71)
Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. (2003) (71)
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial (2018) (70)
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. (2006) (68)
miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites (2016) (68)
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). (2012) (67)
Modulation of Apo‐1/Fas (CD95)‐induced programmed cell death in myeloma cells by interferon‐α2 (1996) (67)
Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future (2013) (67)
Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial. (2019) (67)
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. (2014) (66)
Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer (2018) (66)
Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells (2010) (65)
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. (2019) (64)
A modified scoring of the NCCN‐IPI is more accurate in the elderly and is improved by albumin and β2‐microglobulin (2015) (64)
Digging deep into “dirty” drugs – modulation of the methylation machinery (2015) (64)
Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group (2013) (63)
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. (2016) (63)
Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts (2001) (63)
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). (2014) (62)
Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group. (2019) (61)
Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. (2014) (60)
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study f (2016) (59)
Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. (1991) (59)
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. (2021) (59)
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study (2018) (59)
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma (2011) (58)
Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia (2011) (57)
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. (2014) (57)
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study (2017) (57)
A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM‐1) modulates the release of tumor necrosis factor‐α, interferon‐γ and interleukin 1 (1990) (56)
HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin’s lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG) (2005) (56)
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation (2015) (55)
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation (2017) (54)
Synergistic action of protein kinase C θ and calcineurin is sufficient for Fas ligand expression and induction of a crmA‐sensitive apoptosis pathway in Jurkat T cells (1999) (54)
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. (2016) (54)
Purine antagonists for chronic lymphocytic leukaemia. (2006) (54)
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. (2016) (53)
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. (2019) (53)
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. (2002) (52)
Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults. (1998) (52)
Utility of PCR in Diagnosis of Invasive Fungal Infections: Real-Life Data from a Multicenter Study (2012) (52)
Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). (2010) (50)
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. (2015) (50)
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer. (2000) (50)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer (2009) (50)
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality? (2016) (49)
Canonical and noncanonical Hedgehog/GLI signaling in hematological malignancies. (2012) (49)
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial (2013) (49)
Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) (2012) (49)
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma (2017) (49)
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. (2014) (49)
Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only (2019) (49)
Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia (2015) (48)
Multidimensional scaling as a tool for analysing quality of life data (2002) (48)
Tetrocarcin-A--induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway. (2003) (48)
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. (2008) (47)
Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994. (1999) (47)
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial (2014) (47)
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group (2017) (47)
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials (2011) (47)
Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia (2006) (46)
Expression of Apo‐1/Fas (CD95), Bcl‐2, Bax and Bcl‐x in myeloma cell lines: relationship between responsiveness to anti‐Fas mab and p53 functional status (1997) (46)
The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia (2013) (46)
S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor–Positive Early Breast Cancer. (2011) (46)
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). (2020) (46)
Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. (2000) (46)
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. (2014) (45)
The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. (2009) (45)
Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells (2011) (45)
Longer Failure-Free Survival Interval of Epstein-Barr Virus–Associated Classical Hodgkin's Lymphoma: A Single-Institution Study (2003) (45)
S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC) (2011) (44)
Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia (2002) (43)
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b (2015) (43)
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. (2004) (43)
Abstract S2-02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial (2016) (43)
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients (2014) (43)
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. (2017) (42)
Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia (2010) (42)
Tumour-immune cell interactions modulated by chemokines. (2008) (42)
PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis (2010) (42)
A role of TRAIL in killing osteoblasts by myeloma cells (2006) (42)
LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial (2020) (41)
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. (2016) (41)
IL-4 inhibits the TNF-α induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-α to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses (2006) (41)
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). (2019) (41)
Cytomegalovirus reactivation and its clinical impact in patients with solid tumors (2015) (40)
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR) (2019) (40)
Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? (2019) (40)
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. (1998) (40)
TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia (2017) (39)
Difference in the Relative Distribution of CD4+ T-cell Subsets in B-CLL With Mutated and Unmutated Immunoglobulin (Ig) VH Genes: Implication for the Course of Disease (2009) (39)
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial (2020) (39)
Stressful death of T‐ALL tumor cells following treatment with the antitumor agent Tetrocarcin‐A (2002) (39)
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade (2019) (38)
Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606) (2015) (38)
CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility. (2013) (37)
Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. (2010) (37)
Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target (2012) (36)
Viral infections and their management in patients with chronic lymphocytic leukemia (2013) (36)
The interleukin 1β‐converting enzyme inhibitor CrmA prevents Apo1/Fas‐ but not glucocorticoid‐induced poly(ADP‐ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells (1997) (36)
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study (2012) (36)
Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial) (2019) (36)
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry (2021) (36)
Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. (2004) (36)
The Role of Soluble CD23 in Distinguishing Stable and Progressive Forms of B-chronic Lymphocytic Leukemia (2002) (36)
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17) (2008) (35)
Biomarkers in non-small cell lung cancer prevention (2004) (35)
Splenectomy versus medical treatment for idiopathic thrombocytopenic purpura. (2002) (35)
Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. (2006) (35)
Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. (2014) (35)
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. (2009) (35)
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia (2010) (35)
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones (2016) (34)
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie (2013) (34)
Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade (2014) (34)
Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy (2008) (34)
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. (2014) (34)
Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis. (2005) (34)
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) (2021) (34)
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) (2021) (34)
Multimodal therapy in life-threatening cerebral lupus erythematosus: the benefit of cerebrospinal fluid pheresis. (1995) (33)
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma (2017) (33)
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. (2010) (33)
Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. (2015) (33)
Beacopp Chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12- Trials of the German Hodgkin Study Group (GHSG). (2004) (33)
Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma. (2019) (33)
CAR T-Cell Therapy in Hematological Malignancies (2021) (33)
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia (2014) (33)
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools (2003) (33)
Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study (2018) (33)
IOERT as anticipated tumor bed boost during breast‐conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer—Results of a case series after 5‐year follow‐up (2015) (33)
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications (2016) (33)
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. (2014) (32)
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model (2015) (32)
Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial (2018) (32)
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial (2015) (31)
Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation (2017) (31)
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study) (2012) (31)
Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence (2020) (31)
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study. (1997) (30)
The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07) (2008) (30)
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. (2021) (29)
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. (2021) (29)
Modifying akt signaling in B-cell chronic lymphocytic leukemia cells. (2010) (29)
Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools (2011) (29)
A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients (2013) (28)
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. (2008) (28)
Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. (2018) (28)
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. (2020) (28)
Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor–Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy (2009) (28)
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13 (2008) (28)
The significance of pretreatment anemia in the era of R‐IPI and NCCN‐IPI prognostic risk assessment tools: a dual‐center study in diffuse large B‐cell lymphoma patients (2015) (28)
Mimicking the microenvironment in chronic lymphocytic leukaemia – where does the journey go? (2013) (27)
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up (2015) (27)
Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature (2006) (27)
Constituents of autocrine IL‐6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies (1996) (26)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. (2005) (26)
APOBEC3 signature mutations in chronic lymphocytic leukemia (2014) (26)
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. (2021) (26)
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia (2012) (26)
Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial (2013) (26)
The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis. (2009) (26)
Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors (2016) (26)
Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma (2020) (26)
IMMUNOHISTOLOGY FOR QUANTIFICATION OF NORMAL BONE MARROW LYMPHOCYTE SUBSETS (1989) (26)
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score (2022) (25)
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1 (2014) (25)
Update on squamous cell carcinoma of the head and neck (2017) (25)
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses (2014) (25)
609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) (2020) (25)
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study (2020) (25)
2′,2′‐Difluorodeoxycytidine (Gemcitabine) Induces Apoptosis in Myeloma Cell Lines Resistant to Steroids and 2‐Chlorodeoxyadenosine (2‐CdA) (1996) (25)
Epstein-Barr virus-associated extranodal NK/T-cell lymphoma, nasal type of the hypopharynx, in a renal allograft recipient: case report and review of literature. (2001) (24)
Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG). (2005) (24)
Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer (2008) (24)
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi- center trial by the Austrian Working Group For Medical Tumor Therapy (1997) (24)
Primary gastrointestinal B-cell lymphoma. A clincopathological and immunohistochemical study of 61 cases with an evaluation of prognostic parameters. (2001) (24)
Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? (2007) (24)
DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer (2018) (24)
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe (2018) (24)
A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. (2020) (23)
AID induces intraclonal diversity and genomic damage in CD86+ chronic lymphocytic leukemia cells (2014) (23)
Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer (2011) (23)
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients (2016) (23)
Intravascular large B-cell lymphoma with a fulminant clinical course: a case report with definite diagnosis post mortem. (2002) (23)
Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial (2016) (23)
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study (2015) (23)
BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation (2018) (23)
Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial (2010) (23)
Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12. (2011) (23)
Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma. (2005) (22)
Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study (2015) (22)
Abstract S4-3: The EndoPredict score identifies late distant metastases in ER+/HER2− breast cancer patients (2012) (22)
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. (2022) (22)
Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients (2014) (22)
Monoclonal antibody B-ly7: a sensitive marker for detection of minimal residual disease in hairy cell leukemia. (1990) (22)
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. (2008) (21)
Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination (2019) (21)
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients (2014) (21)
Twelve-year retrospective analysis of lung cancer--The TYROL Study: Daily routine in 1,424 patients (1995-2006) (2008) (21)
The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by “on-demand” addition of plerixafor to granulocyte–colony-stimulating factor (2014) (21)
CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms (2014) (21)
Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity (2019) (21)
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). (2020) (20)
Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin’s lymphoma: Results of the fourth interim analysis of the HD 11 trial of the GHSG (2005) (20)
Improvement of quality of life and psychological distress after inpatient cancer rehabilitation (2017) (20)
Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial. (2016) (20)
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21 (2015) (20)
Circulating tumor DNA to monitor metastatic breast cancer. (2013) (20)
Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. (2009) (20)
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. (2013) (20)
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial (2022) (20)
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study (2017) (20)
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes (2018) (20)
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group. (2018) (20)
53O_PRPREDICTING RISK FOR LATE METASTASIS: THE PAM50 RISK OF RECURRENCE (ROR) SCORE AFTER 5 YEARS OF ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH HR+ EARLY BREAST CANCER: A STUDY ON 1,478 PATIENTS FROM THE ABCSG-8 TRIAL (2013) (20)
Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214). (2012) (20)
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). (2003) (20)
Cure in metastatic breast cancer (2018) (19)
ESMO recommendations for the application of hematopoietic growth factors. (2005) (19)
Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03. (2009) (19)
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs (2014) (19)
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. (2021) (19)
Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study. (2007) (19)
Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial. (2009) (19)
Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia. (2002) (19)
Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients. (2014) (19)
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab (2018) (19)
Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer (2020) (19)
Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycin. (1989) (19)
Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme (2007) (19)
Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study. (2004) (19)
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma (2015) (18)
Smart Home Precipitator for Biomass Furnaces: Design Considerations on a Small-Scale Electrostatic Precipitator (2012) (18)
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC). (2020) (18)
First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa (2016) (18)
Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly (1998) (18)
Importance of an 85 kDa membrane glycoprotein for a variety of cell-cell interactions. (1988) (18)
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL). (2021) (18)
Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). (2016) (18)
B-cell specific IRF4 deletion accelerates Chronic Lymphocytic Leukemia development by enhanced tumor immune evasion. (2019) (18)
Necrotizing vasculitis associated with hepatitis C virus infection: successful treatment of vasculitis with interferon-alpha despite persistence of mixed cryoglobulinemia. (1995) (18)
Tuning the rheostat of the myelopoietic system via Fas and TRAIL. (2003) (17)
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+) (2018) (17)
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM (2019) (17)
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial (1997) (17)
Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11;18) negative, surgically resected, gastrointestinal B cell lymphomas (2004) (17)
Adipocyte-derived players in hematologic tumors: useful novel targets? (2015) (17)
The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia (2015) (17)
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. (2019) (17)
Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA). (2020) (17)
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. (2012) (17)
Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level (2013) (17)
CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues. (2021) (17)
Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial (2018) (17)
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group (2018) (16)
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer (2016) (16)
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population (2020) (16)
Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study. (2014) (16)
Immune checkpoint blockade in ovarian cancer (2016) (16)
Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance. (2017) (16)
Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals (2009) (16)
Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study) (2017) (16)
TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). (2019) (16)
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. (2018) (16)
ASCO 2018 highlights: metastatic breast cancer (2018) (16)
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial (2012) (16)
Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals (2018) (16)
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). (2011) (16)
Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis (2020) (15)
Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma (2019) (15)
KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2020) (15)
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). (2014) (15)
Erythropoietins in cancer patients: ESMO recommendations for use. (2008) (15)
Growth fraction of tumour cells and infiltrationdensity with natural killer‐like (HNK1+) cells in non‐Hodgkin lymphomas (1986) (15)
Interferon-a for the treatment of elderly patients with chronic myeloid leukaemia (1998) (15)
Tumour-immune cell interactions modulated by chemokines (2008) (15)
Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly (1998) (15)
Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG) (2016) (15)
Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG. (2004) (15)
Cytokine priming of the granulocyte respiratory burst in myelodysplastic syndromes. (1997) (15)
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group (2012) (14)
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. (2020) (14)
Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. (2013) (14)
Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. (2020) (14)
Apoptosis and therapy of malignant diseases of the hematopoietic system. (1994) (14)
The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma (2013) (14)
Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial (2014) (14)
Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial (2019) (14)
Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema. (2009) (14)
First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy (2012) (14)
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma (2021) (14)
SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a. (2008) (14)
CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model (2015) (14)
Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development (2018) (14)
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study (2019) (13)
4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24) (2009) (13)
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study (2022) (13)
Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis (2020) (13)
Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer (2011) (13)
Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis (2005) (13)
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study (2022) (13)
In situ quantification of T-cell subsets, NK-like cells and macrophages in hodgkin's disease: Quantity and quality of infiltration density depends on histopathological subtypes (1986) (13)
Is higher income and educational status associated with poorer outcome in patients with Hodgkin's disease? (2004) (13)
Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study (2018) (13)
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? (2009) (13)
Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer (2009) (13)
Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial. (2010) (13)
Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER). (2017) (13)
Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion (2013) (13)
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. (2017) (13)
C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients (2019) (13)
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients (2019) (13)
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie) (2018) (12)
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. (2015) (12)
Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial (2011) (12)
[Urticarial vasculitis as a symptom of Muckle-Wells syndrome?]. (1991) (12)
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: First results of a multicenter phase II trial (AGMT Gastric- 2 (2008) (12)
Cytotoxic Properties of Damiana (Turnera diffusa) Extracts and Constituents and A Validated Quantitative UHPLC-DAD Assay (2019) (12)
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters (2018) (12)
Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study (2012) (12)
Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C (2007) (12)
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. (2021) (12)
O-253 Early intervention with epoetin alfa maintains hemoglobin (HB) in advanced non-small-cell lung cancer (NSCLC) patients (2003) (12)
In situ hybridization for the detection of low copy numbers of c-abl oncogene mRNA in lymphoma cells: technical approach and comparison with results with anti-oncoprotein antibodies. (1989) (12)
Chemotherapy in gastric cancer. (2008) (12)
Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial). (2018) (11)
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors (2014) (11)
The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells (2015) (11)
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. (2021) (11)
Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study (2019) (11)
CDK4/6 inhibition in luminal breast cancer (2016) (11)
Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience. (2017) (11)
ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia. (2016) (11)
CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity (2020) (11)
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer (2015) (11)
Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity (1998) (11)
Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial (2022) (11)
Colorectal Cancer Study Group Trial ( ABCSG ) 8 CYP 2 D 6 Metabolism and Patient Outcome in the Austrian Breast (2013) (11)
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
Vinorelbine/Gemcitabine in advanced non-small-cell lung cancer (1999) (11)
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients (2011) (11)
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform (2008) (11)
Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE (2018) (11)
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value (2010) (11)
PKC is essential for the development of chronic lymphocytic leukemia in the TCL 1 transgenic mouse model : validation of PKC as a therapeutic target in chronic lymphocytic leukemia (2009) (10)
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer (2009) (10)
Chemokine-dependent B cell–T cell interactions in chronic lymphocytic leukemia and multiple myeloma – targets for therapeutic intervention? (2012) (10)
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer (2016) (10)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia. (2005) (10)
Transient congenital dilated cardiomyopathy after maternal R-CHOP chemotherapy during pregnancy. (2017) (10)
miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors (2021) (10)
Intensification of Chemotherapy and Concomitant Reduction of Radiotherapy Dose in Intermediate Stage Hodgkin′s Lymphoma: Results of the Fourth Interim Analysis of the HD 11 Trial of the GHSG. (2004) (10)
B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia (2015) (10)
RNA Editing Alters miRNA Function in Chronic Lymphocytic Leukemia (2020) (10)
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas (2019) (10)
Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study (2013) (10)
Performance Characteristics of the Cobas Ampliprep/Cobas Taqman V2.0 and the Abbott Realtime Hepatitis C Assays - Implications for Response-Guided Therapy in Genotype 1 Infections (2014) (10)
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial. (1997) (10)
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report (2013) (10)
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study (2018) (10)
Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy (2020) (9)
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. (2012) (9)
Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. (2011) (9)
Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study. (2009) (9)
Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia (2017) (9)
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group (2021) (9)
Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia. (2018) (9)
Bone-Targeted Therapy in Metastatic Breast Cancer - All Well-Established Knowledge? (2014) (9)
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM) (2016) (9)
SAMHD1 restrains aberrant nucleotide insertions at repair junctions generated by DNA end joining (2021) (9)
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells (2016) (9)
Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). (2010) (9)
Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer (2015) (9)
Zoledronic acid for adjuvant use in patients with breast cancer (2011) (9)
Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Resections and curative surgery in a phase II single arm, multicenter study (20060314). (2010) (9)
Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results (2013) (9)
Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT). (2008) (9)
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results (2018) (9)
Thymic Hodgkin's disease--a histological and immunohistochemical study of three cases. (1999) (9)
Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy (2017) (9)
SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL (2019) (9)
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3. (2017) (9)
A New Sesquiterpene Lactone Sulfate from Reichardia gaditana (Asteraceae) (2007) (9)
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL. (2019) (9)
A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results (2011) (9)
Chronic Myelomonocytic Leukemia (CMML) (2010) (9)
Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash. (2010) (8)
Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214) (2014) (8)
A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients (2018) (8)
Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial. (2010) (8)
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial) (2018) (8)
Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial. (2009) (8)
AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma) (2015) (8)
Investigation of nuclear c-MYC oncoprotein expression in human hematopoiesis: suitability of a rapid and reliable semiquantitative evaluation system. (1992) (8)
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study (2021) (8)
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer (2021) (8)
[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms]. (2007) (8)
SABCS 2016: systemic therapy for metastatic breast cancer (2017) (8)
Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2021) (8)
Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial) (2019) (8)
Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options (2020) (8)
Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe (2011) (8)
The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. (1997) (8)
Structure-Guided Identification of Black Cohosh (Actaea racemosa) Triterpenoids with In Vitro Activity against Multiple Myeloma (2020) (8)
Hematopoietic growth factors: ESMO recommendations for the application. (2007) (8)
Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]). (2009) (8)
11TiPPhase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048 (2015) (8)
First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant (2011) (8)
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia. (1998) (7)
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV) (2012) (7)
Hodgkin lymphoma in Tyrol—a population-based study (2009) (7)
Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells (2019) (7)
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer. (2019) (7)
Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics (2019) (7)
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC) (2020) (7)
abl oncogene expression in non‐Hodgkin lymphomas: Correlation to histological differentiation and clinical status (1988) (7)
Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera. (2020) (7)
Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia (2014) (7)
Receptors for the third component of complement: their association with maturation stage in non-Hodgkin lymphomas (NHL) and their possible implication with the development of follicular structures. (1986) (7)
Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG‐14 (2011) (7)
Antiangiogenic therapy in breast cancer (2017) (7)
Gastric malt lymphoma with crystalline immunoglobulin inclusions and secondary immunoblastic lymphoma in a cervical lymph node. (1995) (7)
Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT. (2013) (7)
Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. (2014) (7)
Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer. (2012) (7)
Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics. (2019) (7)
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). (2021) (7)
Retreatment with Alemtuzumab after a First, Successful Alemtuzumab Treatment in B-CLL. (2007) (7)
RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia (2020) (7)
HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany. (2006) (7)
Abstract P3-11-06: Bevacizumab in combination with docetaxel+trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study (2015) (7)
The BENDALEM CLL 6 AGMT Study – Bendamustine Combined with Alemtuzumab In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis (2010) (7)
ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. (2005) (7)
5.28 Combining Fludarabine and Rituximab With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia: The REVLIRIT CLL5 AGMT Phase 1/2 Study—Results from Clinical and Exploratory Analyses of Induction (2011) (6)
O-0021 Randomised Phase III Study of Bevacizumab + Chemotherapy Beyond Progression in Bevacizumab-Treated Patients with Metastatic Colorectal Cancer: TML Study Kras Subgroup Findings (2012) (6)
Reversal of acute renal impairment bybortezomib-doxorubicin-dexamathasone in multiple myeloma.Results from an phase II study (2009) (6)
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. (2018) (6)
Evidence for the conversion of docetaxel into 7'-epidocetaxel in patients receiving Taxotere-based conventional chemotherapy. (2010) (6)
Four versus Two Years of Rituximab Maintenance (R‐Maintenance) Following Bendamustine Plus Rituximab (B‐R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First‐Line Follicular Lymphoma (the StiL NHL7‐2008 MAINTAIN Study): FR‐S26‐NHL‐140 (2018) (6)
An uncommon cause of anaemia: Sheehan's syndrome (2010) (6)
Continuous prednisolone versus conventional prednisolone with VMCP–interferon‐α2b as first‐line chemotherapy in elderly patients with multiple myeloma (2005) (6)
Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1–Infected Patients (2017) (6)
IL-10 serum levels in B-cell chronic lymphocytic leukaemia. (1996) (6)
Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway (2000) (6)
Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry (2014) (6)
Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data (2015) (6)
Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype. (2018) (6)
Nuclear proto-oncogene homologous proteins during the cell cycle of Physarum polycephalum (1992) (6)
Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria (2019) (6)
Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study (2013) (6)
Differential Sensitivity of CD 4 1 and CD 8 1 T Lymphocytes to the Killing Efficacy of Fas ( Apo-1 / CD 95 ) Ligand 1 Tumor Cells in B Chronic Lymphocytic Leukemia (1998) (6)
Gastrointestinal tumors, non-colorectal (2012) (6)
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma (2014) (6)
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19 (2022) (6)
PS1161 EFFICACY AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PREVIOUSLY TREATED WITH VENETOCLAX IN THE MURANO STUDY (2019) (6)
Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study (2013) (6)
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer (2020) (6)
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT (2020) (6)
1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma (2020) (6)
Diffuse Large B-cell Lymphoma with Infiltration-Associated Peripheral Neuropathy and Paraneoplastic Myopathy with a Prolonged Course Over Seven Years (2002) (6)
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)]. (2012) (6)
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study (2021) (6)
PKCβ Is Essential for the Development of CLL in the TCL1 Transgenic Mouse Model: Validation of PKCβ as a Therapeutic Target in CLL (2008) (6)
Abstract P5-11-02: The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests That the Benefits of Combining Zoledronic Acid with Adjuvant Endocrine Therapy Persist Long after Completion of Therapy (2010) (6)
1,10-Epoxyhypocretenolides from the Azorean Endemic Leontodon rigens (Asteraceae) (2005) (6)
Kasabach‐Merritt phenomenon in hepatic angiosarcoma (2014) (6)
Imaging , Diagnosis , Prognosis A New Molecular Predictor of Distant Recurrence in ER-Positive , HER 2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (2011) (6)
Vinorelbine/gemcitabine in advanced non-small-cell lung cancer: a phase I trial (1998) (5)
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR) (2016) (5)
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient (2013) (5)
915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (2020) (5)
The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia. (2009) (5)
Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). (2009) (5)
Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study (2016) (5)
Long-term results of dose density therapy in patients with aggressive lymphoma (2005) (5)
Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal ofAcute Light Chain Induced Renal Failure (ARF) in MultipleMyeloma (MM). Results from a Phase II Study (2008) (5)
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (2021) (5)
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel (2021) (5)
CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma (2016) (5)
Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis (2008) (5)
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1 (2020) (5)
Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra (2006) (5)
Dose-dense therapy improves survival in aggressive non-Hodgkin’s lymphoma (2010) (5)
Combined CXCR 3 / CXCR 4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative cooperativity of the receptors (2015) (5)
Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors. (2021) (5)
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine (2019) (5)
Abstract P4-22-20: Efficacy and safety of everolimus plus exemestane in HR+, HER2– advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2ndinterim analysis from STEPAUT (2017) (5)
Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis (2019) (5)
The number needed to treat (NNT) as a measure of drug efficacy: the case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial. (2009) (5)
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (2020) (5)
The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial. (2006) (5)
Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians (2011) (5)
Lignans and sesquiterpene lactones from Hypochaeris radicata subsp. neapolitana (Asteraceae, Cichorieae). (2019) (5)
Efficacy of Temsirolimus after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer (2011) (5)
Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (2010) (5)
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial (2021) (5)
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1 (2018) (5)
Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated (2012) (5)
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial (2020) (5)
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study (2022) (5)
Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial (2019) (4)
Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations (2018) (4)
Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study (2017) (4)
Conventional Clinical Risk Factors HER 2-Negative Breast Cancer Adds Independent Information to A New Molecular Predictor of Distant Recurrence in ER-Positive (2011) (4)
Is Chemoendocrine Treatment without Alternative? (2008) (4)
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. (2022) (4)
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial (2022) (4)
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target? (2020) (4)
The Still Long and Winding Road to Neoadjuvant Sytemic Therapy as the Standard of Care in Breast Cancer (2006) (4)
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. (2021) (4)
101 Age- and comorbidity-specific evaluation of azacitidine treatment, response and overall survival in 184 patients in the Austrian Azacitidine Registry (2011) (4)
Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study (2021) (4)
The Spiegelmer® Nox-A12 Abrogates Homing Of Human CLL Cells To Bone Marrow and Mobilizes Murine CLL Cells In The Eμ-TCL1 Transgenic Mouse Model Of CLL (2013) (4)
Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera Study (2013) (4)
Transcatheter aortic valve implantation in a patient with suspected hereditary von Willebrand disease and severe gastrointestinal bleeding – a case report (2019) (4)
Preoperative oxaliplatin (O), capecitabine (X), and external beam radiotherapy (RT) in patients (pts) with newly diagnosed, primary operable, locally advanced rectal cancer (LARC) (2007) (4)
Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. (2012) (4)
Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial (2016) (4)
Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02) (2019) (4)
Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC) (2012) (4)
VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions (2015) (4)
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group (2019) (4)
Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity (2012) (4)
Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics (2015) (4)
Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial (2017) (4)
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis (2018) (4)
5018 Quality of life (QoL) in patients (pts) treated with bevacizumab (BV) and taxane therapy for locally recurrent (LR) or metastatic breast cancer (mBC) (2009) (4)
Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry (2014) (4)
The Dark Side of the Moon – the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management (2009) (4)
Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy (2019) (4)
Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer (2020) (4)
Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia (2018) (4)
CXCL 12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells : a role for CCL 21 (2015) (4)
The relationship between quality of life (QoL) and tumor response in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab (pmab) plus FOLFIRI as first-line therapy: An analysis of study 314. (2011) (4)
Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy (2013) (4)
Abstract PD09-05: Impact of Body Mass Index (BMI) on the Efficacy of Endocrine Therapy in Postmenopausal Breast Cancer Patients — An Analysis of the ABCSG 6 and 6a Trial (2010) (4)
Nonmetastatic pancreatic cancer (2018) (4)
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping. (2016) (4)
Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study (2010) (4)
A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with stage II colon cancer (2007) (4)
Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. (2016) (4)
Oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. Final results of a multicenter phase II trial. (2006) (4)
Phase II study of bortezomib, thalidomide, and dexamethasone /-cyclophosphamide as induction therapy in previously untreatedmultiple myeloma (MM): safety and activity including evaluationof MRD (2010) (4)
Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network (2020) (4)
Planned First Safety and Efficacy Analysis of Oral Fludarabine Combined with Subcutaneous Alemtuzumab in 2 nd Line Therapy of B-Chronic Lymphocytic Leukaemia (B-CLL): The FLUSALEM Study. (2006) (4)
BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT (2012) (4)
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. (2021) (4)
Epidermal growth factor receptor (EGFR) inhibitor-related skin toxicity: Review of interim data from a phase II study (20060314) of panitumumab (pmab) with FOLFIRI in the first-line treatment of metastatic colorectal cancer (mCRC). (2009) (4)
Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial. (2022) (4)
Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison (2018) (4)
Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights. (2009) (4)
A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort. (2020) (4)
Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes (2014) (4)
Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients (2020) (3)
Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16- (2013) (3)
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor (2021) (3)
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia (2016) (3)
Dose Escalation of Ara-C May Improve Response Rates in a Subgroup of Chronic Myeloid Leukemia Patients with Poor Response to Interferon-α and Low-dose Ara-C (2001) (3)
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial. (2019) (3)
100 Overall survival data of patients with MDS, AML and CMML from the Austrian Azacitidine Registry of 184 consecutive patients (2011) (3)
Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy? (2015) (3)
Lenalidomide As Maintenance Therapy after R-CHOP Has No Protecting Effect for Central Nervous System Relapse in Frontline Treatment of Diffuse Large B-Cells Lymphoma. an Ancillary Studies of the Remarc Study (2020) (3)
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort (2022) (3)
Cytotoxic Compounds of Two Demosponges (Aplysina aerophoba and Spongia sp.) from the Aegean Sea (2021) (3)
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial. (2021) (3)
Human immunodeficiency virus type 2 infections in Austria (2014) (3)
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial (2019) (3)
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma (2019) (3)
Contents, Vol. 105, 1994 (1994) (3)
Prognostic Significance of CD 20 Expression in Classical Hodgkin Lymphoma : A Clinicopathological Study of 119 Cases 1 (2003) (3)
Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147. (2013) (3)
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group (2022) (3)
Eight Cycles of Escalated-Dose BEACOPP Compared With FourCycles of Escalated-Dose BEACOPP Followed by Four Cycles ofBaseline-Dose BEACOPP With or Without Radiotherapy in PatientsWith Advanced-Stage Hodgkin’s (2011) (3)
Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial. (2011) (3)
283P Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry (2021) (3)
Re-sensitizing tumor cells to cancer drugs with epigenetic regulators. (2021) (3)
Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles (2021) (3)
Novel treatment avenues for peripheral T-cell lymphomas (2012) (3)
Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial (2022) (3)
Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial) (2020) (3)
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC). (2020) (3)
A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation? (2015) (3)
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 by the GHSG (2019) (3)
Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. (2020) (3)
Abstract P5-17-03: Quality of life (QoL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC) (2012) (3)
Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. (2015) (3)
Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol (2022) (3)
Abstract P6-10-01: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34) (2017) (3)
Transcriptomic Profiling Identifies CD8+ T Cells in the Brain of Aged and Alzheimer’s Disease Transgenic Mice as Tissue-Resident Memory T Cells (2022) (3)
A case of long‐term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab‐refractory chronic lymphocytic leukaemia with deletion 17p (2013) (3)
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. (2021) (3)
Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry (2020) (3)
Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy (2020) (3)
Prospective screening for human epidermal growth factor receptor 2 (HER2) positivity in patients with inoperable locally advanced or metastatic gastric or gastro-esophageal junction cancer. AGMT gastric-5. (2014) (3)
Renal safety of intravenous ibandronate 6mg infused over 15 or 60 minutes in patients with breast cancer and bone metastases: A randomized, open-label study (2007) (3)
PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy. (2016) (3)
Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB) (2020) (3)
Primary operation in synchroneous metastasized invasive breast cancer patients: First oncologic outcomes of the prospective randomized phase III ABCSG 28 POSYTIVE trial. (2017) (3)
Abstract P4-07-03: MicroRNAs correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer (2015) (2)
Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program. (2018) (2)
Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study (2018) (2)
Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial (2021) (2)
Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy (2020) (2)
The Application of G-CSF and GM-CSF as an Adjunct to Chemotherapy in Clinical Practice: Perspectives and Challenges (1993) (2)
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial (2019) (2)
MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer (2010) (2)
Abstract GS6-04: The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34 (2018) (2)
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial (2023) (2)
ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study (2021) (2)
S1616 MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG) (2019) (2)
62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer (2011) (2)
Erythropoietins in cancer patients: ESMO recommendations for use. (2007) (2)
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study. (2014) (2)
Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. (2021) (2)
AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL (2021) (2)
1447P S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO (2020) (2)
Top 3 abstracts concerning hormone-receptor-positive early breast cancer (2021) (2)
Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT (2022) (2)
EXTENSIVE MENINGEAL INVOLVEMENT AS THE PRIMARY MANIFESTATION OF A SYSTEMIC SMALL LYMPHOCYTIC LYMPHOMA: FAVOURABLE OUTCOME AFTER NEURAXIAL IRRADIATION WITHOUT CHEMOTHERAPY (1993) (2)
Abstract P5-20-11: Bevacizumab in metastatic breast cancer: a retrospective matched-pair analysis. (2012) (2)
Kindlin‐3 maintains marginal zone B cells but confines follicular B cell activation and differentiation (2021) (2)
Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m2) and Triple T with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma (An Interim Analysis). (2006) (2)
Topical evening primrose oil for reduction of bortezomib-induced skin reactions (2013) (2)
172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) (2020) (2)
Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study (2011) (2)
Detecting Bacterial–Human Lateral Gene Transfer in Chronic Lymphocytic Leukemia (2022) (2)
Polycythemia Vera (PV) (2010) (2)
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). (2022) (2)
Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature (2021) (2)
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation (2017) (2)
Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score (2015) (2)
Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia (2022) (2)
Treatment of invasive aspergillosis in cancer patients (2011) (2)
Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial. (2012) (2)
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer? (2014) (2)
O-0020 Bevacizumab + Chemotherapy Beyond First Progression in Metastatic Colorectal Cancer Patients Previously Treated with Bevacizumab-Based Therapy: TML Study Subgroup Findings (2012) (2)
538P Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC) (2021) (2)
Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders (2008) (2)
Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group (2011) (2)
Deletion of Puma and p21Waf1 In Mice Deactivates p53-Induced Cell Death and Cell Cycle Arrest, but Protects Mice From Irradiation-Induced Lymphomagenesis by a Mechanism Involving Hemopoietic Stem Cell Quiescence (2010) (2)
A POLE Splice Site Deletion Detected in a Patient with Biclonal CLL and Prostate Cancer: A Case Report (2021) (2)
Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab. (2011) (2)
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence (2021) (2)
1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) (2015) (2)
REACHAUT: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) in the real-world setting. (2019) (2)
Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines: Final results of a phase I/II study (2007) (2)
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis (2014) (2)
Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg—a report from the AGMT COVID-19 Registry (2021) (2)
Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group (2019) (2)
Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma (2014) (2)
Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome (2014) (2)
Cytotoxic constituents and a new hydroxycinnamic acid derivative from Leontodon saxatilis (Asteraceae, Cichorieae) (2021) (2)
Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the ABCSG Trial 5 (2020) (2)
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies (2021) (2)
Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and IF-RT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial (2008) (2)
Bisphosphonates as adjuvant therapy for breast cancer (2009) (2)
Abstract P4-08-05: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years (2019) (1)
Validation of genetic variants from NGS data using deep convolutional neural networks (2022) (1)
Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: Final efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the arbeitsgemeinschaft Medikamentöse tumortherapie (AGMT). (2011) (1)
The role of biomarkers in the choice of therapy in breast cancer (2012) (1)
Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML) (2015) (1)
TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia (2020) (1)
DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial. (2015) (1)
A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (2014) (1)
Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR (2019) (1)
Remission maintenance treatment options in chronic lymphocytic leukemia. (2018) (1)
Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34. (2018) (1)
Short review – Management of Immune Thrombocytopenia in adults (2010) (1)
Improved risk assessment in B-cell chronic lymphocytic leukemia based on sex-specific molecular profiling (2007) (1)
3.22 Diversity of T-Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia (2011) (1)
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study (2012) (1)
Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer. (2015) (1)
Alemtuzumab Is Effective in Patients with Advanced, Pretreated B-Cell Chronic Lymphocytic Leukemia: A Nationwide Study of Routine Use in Austria. (2005) (1)
Myelodysplastic Syndromes (MDS) (2010) (1)
Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial (2017) (1)
[Rhabdomyolysis as a late complication of anesthesia--a case of malignant hyperthermia?]. (1985) (1)
patients with B-chronic lymphocytic leukemia Expression levels of CD38 in T-cells predict for course of disease in male (2013) (1)
Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study (2013) (1)
POWER: An open-label, randomized phase III trial of cisplatin and 5-FU with or without panitumumab (P) for patients (pts) with nonresectable, advanced, or metastatic esophageal squamous cell cancer (ESCC). (2013) (1)
Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia (2019) (1)
Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission. (2008) (1)
Management of immunosuppression in the treatment of chronic lymphocytic leukemia (2013) (1)
T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group (2022) (1)
Comprar Chronic Myeloid Neoplasias and Clonal Overlap Syndromes · Epidemiology, Pathophysiology and Treatment Options | Greil, Richard | 9783211798911 | Springer (2009) (1)
Planned First Efficacy and Safety Analysis of De-Intensified Induction with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos Stud (2007) (1)
Efficacy of neoadjuvant bevacizumab (Av), capecitabine (X), and docetaxel (T) for invasive breast cancer (BC): Phase II result (2008) (1)
Malignant Lymphoblasts in T Cell Acute Lymphoblastic Leukemia Express High Levels of Kv1.3 (2014) (1)
Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). (2022) (1)
Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry (2022) (1)
Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer – Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT) (2021) (1)
Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in th (2008) (1)
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma: Data of real-world utilization in Austria. (2019) (1)
5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial (2009) (1)
Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study (2014) (1)
Cisplatin and 5-Fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase 3 AIO/EORTC Trial (Power) (2019) (1)
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6) (2021) (1)
Relative distribution of CD4+ naïve and memory T-cell subsets independently predicts course of disease in B-CLL (2005) (1)
Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14) (2010) (1)
Renal safety profile of ibandronate 6mg infused over 15 or 60 min in breast cancer patients with bone metastases (2008) (1)
209PQuality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax®) in the preoperative treatment of women with primary breast cancer (ABCSG-34) (2017) (1)
Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer (2022) (1)
OC-0270 Antihormones with or without irradiation in breast cancer: 10-year results of the ABCSG 8A trial (2019) (1)
ASH 2012 update chronic lymphocytic leukemia—the best is yet to come (2013) (1)
Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance (2017) (1)
A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) – AGMT_CMML 1 (2014) (1)
P-76 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer (2020) (1)
Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010 (2011) (1)
An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer (2016) (1)
Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry (2021) (1)
92PLow expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial (2017) (1)
Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa (2020) (1)
Prognostic and Predictive Value of the Tumor-Stroma Ratio in STAGE II Colon Cancer (2020) (1)
A new trisaccharide derivative from Prenanthes purpurea (2011) (1)
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy (2021) (1)
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis (2021) (1)
Systemic treatment of metastatic breast cancer: SABCS 2018 (2019) (1)
Multi-gene signatures in breast cancer: actual clinical impact (2014) (1)
How We Treat Localized Rectal Cancer—An Institutional Paradigm for Total Neoadjuvant Therapy (2022) (1)
Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study. (2013) (1)
Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study (2022) (1)
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone (2021) (1)
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud (2015) (1)
Clonal Diversity of the T Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia (2011) (1)
Expression Levels of CD38 in Tumor Cells and T-Cells Are of Prognostic Value in B-CLL. (2005) (1)
436P Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC) (2021) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. (2015) (1)
Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy (2021) (1)
Differential expression of c-myc-mRNA and c-MYC-protein during terminal neoplastic B-cell differentiation. (1992) (1)
A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results. (2018) (1)
T Cell Exhaustion Contributes to Immune Evasion in Chronic Lymphocytic Leukaemia (2012) (1)
Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study. (2018) (1)
Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma (2008) (1)
340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (2020) (1)
Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome (2013) (1)
DPYD Genotyping to Predict Adverse Events Following TreatmentWith Fluorouracil-Based Adjuvant Chemotherapy in PatientsWith Stage III Colon Cancer (2016) (1)
Postoperative chemoradiotherapywith cisplatin is superior to radioimmunotherapywith cetuximab and radiotherapy alone Analysis of the Austrian head and neck cancer registry of the AGMT (2021) (1)
The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemia (2021) (1)
Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance (2018) (1)
Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients (2021) (1)
Molecular Remission after Induction Chemo- Immunotherapy and Rituximab Maintenance in Previously Untreated Follicular Lymphoma. (2009) (1)
P286 Preplanned subgroup analysis of ABCSG-12 suggests that benefits of adjuvant zoledronic acid (ZOL) are most pronounced in lowest estrogen environment (2011) (1)
Monoclonal gammopathy of undetermined significance. (2002) (1)
[Safety of immunosuppressants]. (2012) (1)
Response to comment by P. Vassilakopoulos and colleagues (2015) (1)
35PMiR-16 is the most stable-expressed housekeeping microRNA in breast cancer tissues from primary and metastatic sites (2015) (1)
What’s new in Hodgkin’s lymphoma: ASH 2012 and more (2013) (1)
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34 (2021) (1)
Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with Bev-Based Therapy: Overall Survival Subgroup Findings from ML18147 (2012) (1)
Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. (2020) (1)
Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study (2014) (1)
PD-0025DISEASE PROGRESSION PATTERNS/OUTCOME BY DISEASE EXTENT FOLLOWING BEVACIZUMAB + CHEMOTHERAPY BEYOND FIRST DISEASE PROGRESSION IN PREVIOUSLY TREATED MCRC (ML18147 STUDY) (2013) (0)
Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG) (2013) (0)
Editorial Board (2010) (0)
Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient (2012) (0)
Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)] (2010) (0)
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group (2012) (0)
Post San Antonio 2020 Update (2021) (0)
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort (2022) (0)
Essential Thrombocythemia (ET) (2010) (0)
Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib (2013) (0)
Time-to-Treatment in Chronic Myelomonocytic Leukemia - a Novel Prediction Model (2016) (0)
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology (2015) (0)
PCN141 QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) FROM THE AVADO STUDY: THE IMPORTANCE OF IMPUTATION METHODS FOR HANDLING MISSING DATA (2009) (0)
The single nucleotide polymorphism MDM2-SNP309 predicts for sensitivity of B-CLL cells to the non-genotoxic activator of the p53 pathway Nutlin-3a (2008) (0)
Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the P (2022) (0)
Multicenter phase II study evaluating docetaxel (D) and cisplatin (C) as an induction regimen prior to surgery or radiochemotherapy (RCT) with D, followed by adjuvant D in chemonaive patients with NSCLC: TAX-AT1–203 (2007) (0)
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Efficacy results of a phase II trial (AGMT MBC-6). (2016) (0)
Prospective Phase III Trial Of Valproic Acid (VPA) In Combination With All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy For AML In Older Patients: Final and Molecular Subset Analyses Of The AMLSG 06-04 Study (2013) (0)
Increased Palmitoylation Modulates Cytoskeletal Regulators to Enhance CXCR4-Mediated Motility of Malignant B Cells (2017) (0)
Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial (2021) (0)
Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study) (2021) (0)
Treatment-induced amenorrhea improves prognosis of early, ER/PR-positive breast cancer (2007) (0)
Abstract P1-13-12: [bold]The adjuvant PANTHER study - A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxel – First report on q (2012) (0)
Abstract P4-09-02: Prognostic and Predictive Value of Centrally Reviewed Ki67 Labeling Index in Postmenopausal Women with Endocrine-Responsive Breast Cancer: Results from Austrian Breast and Colorectal Cancer Study Group Trial 8 (2010) (0)
Book Review / Announcements (1995) (0)
T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcl1 Transgenic Chronic Lymphocytic Leukemia Model (2008) (0)
Abstract P1-04-02: Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial (2022) (0)
転移性結腸直腸癌(MCRC)患者におけるパニツムマブ+FOLFIRIの一次療法研究(20060314)の患者‐報告成績(PRO) (2010) (0)
University of Birmingham MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia (2014) (0)
6007 ORAL MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukaemia but can be preferentially targeted by the MDM2 inhibitor Nutlin-3a (2007) (0)
Recombinant Human Erythropoietin in the Anemia Associated With Multiple Myeloma or Non-Hodgkin’s Lymphoma: Dose Finding and Identification (2000) (0)
Rituximab Plus Subcutaneous Cladribine in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa Associated Tissue (MALT-LYMPHOMA): A Phase II Study by the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie) (2012) (0)
Randomized comparison of neoadjuvant docetaxel (D), epirubicin (E) and pegfilgrastim (P) (+ trastuzumab [T] in HER2+ patients [pts]) with and without capecitabine (C) for operable breast cancer (BC): Results of a planned safety analysis of ABCSG 24 (2007) (0)
Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry (2019) (0)
Abstract P3-10-07: T5 Is a New Molecular Predictor of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Breast Cancer (2010) (0)
A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting (2020) (0)
Abstract 1108: Subtype specific expression of immnune-modulating miR-155 and miR-146a in anaplastic large cell lymphoma (2012) (0)
REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH‐RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R‐CHOP (2017) (0)
Abstract P6-07-10: DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer (2017) (0)
Treating T-cell lymphoma: is there a light at the end of the tunnel? (2012) (0)
Abstract P3-10-07: A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial (2019) (0)
Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry (2022) (0)
PF442 TREATMENT WITH 5-AZACYTIDINE RESULTS IN EXPRESSION OF LONG TERMINAL REPEAT (LTR) ELEMENTS IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH MDS AND AML: FIRST PILOT STUDY (2019) (0)
Abstract PS12-21: First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry (2021) (0)
Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report (2021) (0)
The Nationwide Austrian Registry: a prospective data collection on epidemiology; therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients (2020) (0)
Poster: ABCL-052 MINDway: A Phase Ib/II Dose Optimization Study to Assess Safety and Pharmacokinetics of Tafasitamab + Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2022) (0)
Phase II study of the multikinase inhibitor dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine resistant HER2-/HR+ breast cancer. (2012) (0)
Abstract P2-08-21: Stromal co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer (2016) (0)
Recommendations from the society for diagnosis and therapy of haematological and oncological diseases Guideline Breast Cancer in Women (2016) (0)
Hematopoietic growth factors: ESMO recommendations for the applications. (2008) (0)
Final results of a randomized comparison of infusional 5-fluorouracil/leucovorin plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) in metastatic colorectal carcinoma (MCRC) (2006) (0)
A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report (2012) (0)
[Successful cancer therapy: chance and challenges]. (2013) (0)
Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) + FOLFIRI in metastatic colorectal cancer (mCRC). (2015) (0)
Report on Response and Overall Survival of 128 Unselected, Consecutive AML Patients From the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group (2011) (0)
COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)—A two-cohort phase II study. (2017) (0)
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer (2015) (0)
PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group (2021) (0)
PS1509 QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION (2019) (0)
[71-year old woman with neutropenic fever during chemotherapy]. (2013) (0)
What paths are open for tackling increasing azole resistance in Aspergillus in the clinic? (2012) (0)
Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma (2021) (0)
T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial. (2022) (0)
Abstract OT-37-01: Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18 (2021) (0)
Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol (2016) (0)
Abstract 603: CAL-101 acts synergistic with arsenic trioxide in chronic lymphocytic leukemia by preventing p21 phosphorylation through AKT1. (2013) (0)
Triple Negative Breast Cancer (2010) (0)
CARIATIDE (Compliance of Aromatase Inhibitors Assessment In Daily practice through Educational approach) (2009) (0)
15th Annual Meetings: Association for Oncology of the Upper Rhine (AOR) (1998) (0)
KCa3.1 Blockers Inhibit Cell Proliferation in Chronic Lymphocytic Leukemia (2012) (0)
88 : CXCR3 modulates CXCL12-mediated cellular responses in chronic lymphocytic leukemia (2013) (0)
Experimental treatment of brain metastases (2008) (0)
Abstract P6-21-02: Withdrawn (2019) (0)
Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial) (2022) (0)
The Transcription Factor IRF4 Is Crucial for CLL Progression and Regulates Survival and Proliferation in a Microenvironment Related Manner (2014) (0)
Therapy with JAK 1/2 inhibitors for myelofibrosis (2013) (0)
The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells (2023) (0)
Low-Dose Radiat ion Is Sufficient for the Noninvolved (2001) (0)
Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target (2011) (0)
Editorial Board (2009) (0)
Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF) (2012) (0)
Abstract P2-11-15: Focal ESR1 gene amplification is an independent prognostic marker in postmenopausal patients with endocrine-responsive early breast cancer (2023) (0)
The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling (2017) (0)
Multimodality treatment approaches in pancreatic cancer: Current status and future perspectives (2002) (0)
Editorial Board (2011) (0)
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6) (2016) (0)
0138 ABCSG-16/SALSA: Prospective, open, randomised, multicentre phase III study to assess extended adjuvant treatment with 2 or 5 years' anastrozole in postmenopausal women with endocrine-responsive early breast cancer after 5 years of initial adjuvant endocrine therapy (2009) (0)
Abstract P4-02-02: Contrast-enhanced MRI does not accurately predict pathologic complete response (pCR) after neoadjuvant chemotherapy in early or locally advanced breast cancer (2018) (0)
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study (2018) (0)
Subject Index, Vol. 107, 1995 (1995) (0)
Acknowledgement to Reviewers (2007) (0)
elderly patients with multiple myeloma Thalidomide-dexamethasone compared with melphalan-prednisolone in (2009) (0)
Alemtuzumab in B-Cell Prolymphoytic Leukemia (B-PLL) and Richter’s Transformation. (2006) (0)
Effect of metformin on progression-free survival outcomes in patients with advanced or metastatic HR+, HER2– breast cancer: subgroup analysis of STEPAUT (2017) (0)
The Austrian Fulvestrant Registry: Results from a prospective observation of fulvestrant in postmenopausal patients (2008) (0)
Immunologic profile of hepatic microarchitecture and infiltrating immunocompetent cells in normal livers and changes in reactive and transplanted livers (1989) (0)
Bcl-2-independent pathway Tetrocarcin-A-induced ER stress mediates apoptosis in B-CLL cells via a (2013) (0)
P11.28 Point of use water filters for haemato-oncology patients: do they have a measurable effect on nosocomial waterborne diseases? (2010) (0)
Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study (2022) (0)
De novo “Classic” Paroxysmal Nocturnal Hemoglobinuria (PNH) (Marchiafava-Micheli Syndrome) (2010) (0)
ifying Akt Signaling in B-Cell Chronic R phocytic Leukemia Cells (2010) (0)
Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC (2022) (0)
A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients (2022) (0)
Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG) (2014) (0)
Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG) (2019) (0)
8 Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC) (2010) (0)
Antihormonal treatment with or without whole breast irradiation in low risk breast cancer patients after breast conserving surgery: 10-year results of the ABCSG 8A trial (2019) (0)
OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial. (2011) (0)
Pleural decortication of a marginal zone lymphoma (2014) (0)
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) (2021) (0)
Mouse models to decipher anti-tumor immunity (2019) (0)
The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry - a Prospective Cohort Study By the AGMT Study Group (2021) (0)
Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial (2022) (0)
Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer (2015) (0)
Abstract P5-06-29: Prognosis of triple negative metastatic breast cancer (MBC): Results from the AGMT_MBC-Registry (2020) (0)
Subject Index, Vol. 105, 1994 (1994) (0)
Abstract P3-11-03: Survival and Patterns of Recurrence Following Conservative Treatment in Triple Negative and Triple Positive Breast Cancers (2010) (0)
6073 Interim analysis of epidermal-growth factor receptor (EGFR) expression in a single-arm, phase II, first-line study (20060314) of panitumumab with FOLFIRI in the management of metastatic colorectal cancer (mCRC) (2009) (0)
262PDDOCETAXEL + TRASTUZUMAB +/- NON-PEGYLATED LIPOSOMAL DOXORUBICIN +/- BEVACIZUMAB IN THE NEOADJUVANT TREATMENT OF EARLY, HER2-POSITIVE BREAST CANCER: FIRST RESULTS OF ABCSG-32. (2014) (0)
[Cytologic molecular detection of oncogene expression: possibilities and prospects in hemato-oncology]. (1990) (0)
Abstract OT2-2-03: Dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine-resistant HER2–/HR+ breast cancer: a phase II study (2012) (0)
Editorial Board (2010) (0)
miRNA expression and function in ALK+ and ALK- anaplastic large cell lymphoma (2011) (0)
Abstract P3-07-43: DNA methylation patterns correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer (2016) (0)
Cytomegalovirus reactivation and its clinical impact in patients with solid tumors (2015) (0)
Abstract OT3-07-01: Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial) (2018) (0)
Abstract P4-01-27: Prognosis and treatment landscape of HER2-positive metastatic breast cancer (MBC) before the availability of tucatinib and trastuzumab-deruxtecan: Results from the Austrian AGMT_MBC-Registry (2023) (0)
Academic clinical trials in the 21st century – where do we go from here? The research approach of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) (2008) (0)
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR) (2019) (0)
myeloma well-tolerated regimen in patients with relapsed or refractory multiple Bendamustine-bortezomib-dexamethasone is an active and (2014) (0)
Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC) (2016) (0)
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group (2023) (0)
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie) (2017) (0)
Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial) (2020) (0)
Breast Care (2010) (0)
Chronic Lymphocytic Leukemia Cells With Trisomy 12 Home To The Bone Marrow In a CXCR4-Independent Manner and Are Prone To Proliferate In Vitro (2013) (0)
S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP (2019) (0)
Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial (2021) (0)
Abstract P1-08-13: Predictive value of intrinsic luminal subtypes in premenopausal women with endocrine-responsive early breast cancer: Results from Austrian breast and colorectal cancer study group trial 5 (2013) (0)
Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device (2016) (0)
Abstract CT160: Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial) (2018) (0)
Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results Fro (2022) (0)
BIRC3 but Not BIRC2 mRNA Expression in Chronic Lymphocytic Leukemia Correlates with Disease Progression and Mediates Decreased Fludarabine Sensitivity in Vitro (2012) (0)
Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG) (2010) (0)
Editorial Board (2011) (0)
Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC). (2015) (0)
1552P Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX (2020) (0)
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab (2019) (0)
[Studies of immunologic markers in malignant lymphomas: diagnostic and prognostic relevance]. (1986) (0)
Risks and chances of aberrant DNA repair in cancer (2018) (0)
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT (2023) (0)
Title: The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemia Short title: NLRP3 drives cell cycle progression in AML (2021) (0)
Prognostic value of [18F]FDG PET/CT on treatment response and progression-free survival of gastroesophageal cancer patients undergoing perioperative FLOT chemotherapy. (2023) (0)
Lack of Bmf Facilitates the Selection of Highly Responsive B-Cell Receptor Clones in Chronic Lymphocytic Leukemia (2021) (0)
Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study (2020) (0)
Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study. (2017) (0)
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia (2018) (0)
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer (2023) (0)
Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil Followed by Radiotherapy with Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (2012) (0)
Abstract 2273: Validation of putative stem cell factor SOX2 as predictive marker in breast cancer – with overall poor prognosis (2011) (0)
Impact of Number of Previous Treatment Lines and Pre-Treatment with Bortezomib or Lenalidomide on Efficacy of Bortezomib-Bendamustine-Dexamethasone (BBD) in Patients with Relapsed/Refractory Multiple Myeloma (MM) (2012) (0)
Abstract P3-05-49: Number of involved organs at baseline is prognostic for overall survival in patients with metastatic breast cancer: Results from the AGMT_MBC-Registry (2023) (0)
6th International Meeting on Progress in Radio-Oncology, ICRO/ÖGRO 6 (1998) (0)
A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (2012) (0)
Oxaliplatin, Irinotecan, Bevacizumab followed by Docetaxel, Bevacizumab in Inoperable Gastric Cancer. A Multicenter Phase II Trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) (2012) (0)
[Infiltration pattern of immunocompetent lymphocytes in the tissue of malignant non-Hodgkin's lymphoma: relationship to histological and clinical parameters]. (1985) (0)
10 Clonal Bone Marrow Failure Overlap Syndromes (0)
Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group (2015) (0)
Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient (2015) (0)
Cyclin D1 expression in breast cancer patients and tamoxifen therapy (2007) (0)
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report (2013) (0)
4.23 MDM2 Promotor Polymorphism and Disease Characteristics in CLL: Individual Patient Data Meta-Analysis of 2598 CLL Patients (2011) (0)
Multicenter phase II study evaluating Dxl/Cis as induction regimen prior to surgery or radiochemotherapy in stage II-IIIB NSCLC patients (TAX-AT 1.203) (2014) (0)
Independent validation of stromal uPA in archived tumor samples from the prospectively randomized ABCSG8 trial to provide level 1b evidence for a prognostic value of uPA immunohistochemistry in endocrine-treated postmenopausal breast cancer patients. (2017) (0)
PF679 REAL-WORLD SAFETY DATA FROM A NONINTERVENTIONAL LONG-TERM POSTAUTHORIZATION SAFETY STUDY OF RUXOLITINIB IN MYELOFIBROSIS (2019) (0)
Regulation of apoptosis (2007) (0)
ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III (2022) (0)
Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. (2021) (0)
Rare Clonal Myeloid Diseases (2010) (0)
1422OCTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians’ and patients’ scoring of toxicity in the “Panther trial” (2017) (0)
P-80 TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (2019) (0)
Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC). (2023) (0)
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial (2012) (0)
Editorial Board (2009) (0)
Evidence for the Conversion of Docetaxel into 7-Epidocetaxel in Patients Receiving Conventional Taxotere® Based Chemotherapy (2014) (0)
The fibrinogen/CRP ratio as a novel prognostic parameter for pancreatic cancer patients. (2016) (0)
Abstract P1-17-05: The impact of clinical risk assessment versus PAM-50 ROR score on prognosis and therapeutic decision making in patients with hormone-receptor positive early stage breast cancer (2019) (0)
Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study) (2020) (0)
Vol. 5, Issue 1, March 2010 · Band 5, Heft 1, März 2010 (2010) (0)
Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network (2022) (0)
Abstract P3-08-29: Landscape of HER2-low metastatic breast cancer (MBC): Results from the AGMT-MBC-Registry (2020) (0)
5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data (2011) (0)
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial. (2019) (0)
Kongressankündigungen Congress Announcements (2009) (0)
The single nucleotide polymorphism MDM2-SNP309 influences sensitivity of B-CLL cells to the non-genotoxic activator of the p53 pathway Nutlin-3a (2008) (0)
Myeloma-derived CCL27 induces stroma-dependent resistance against bortezomib via upregulation of IL-10 (2015) (0)
2098 Assessment of pharmacokinetic (PK) interaction between cetuximab (CTX) and capecitabine (CCB) or oxaliplatin (OX) in metastatic colorectal cancer (mCRC) patients (pts) (AGMT_CAPECET_PK) (2015) (0)
Clonal Bone Marrow Failure Overlap Syndromes (2010) (0)
Barriers to patient access of CAR T cell therapies in Austria (2023) (0)
Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia (2021) (0)
Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study within Various Cytogenetic Risk Categories (2008) (0)
Real-World multicenter Austrian analysis of the safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer (2018) (0)
ABCL-052 MINDway: A Phase Ib/II Dose Optimization Study to Assess Safety and Pharmacokinetics of Tafasitamab + Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma. (2022) (0)
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8 (2021) (0)
599PReal life registry data of primary localisation of a well-defined colon cancer population of western Austria (Salzburg, Tyrol and Vorarlberg), eastern Switzerland (St. Gallen and Graubünden) and Liechtenstein (2017) (0)
Good Response of Lupus Hepatitis to Mycophenolate Mofetil and Belimumab as of Lupus Exanthema to Rituximab: A Case Report (2019) (0)
PD PHASE III TRIAL EVALUATING THE ADDITION OF BEVACIZUMAB TO ENDOCRINE THERAPY AS FIRST-LINE TREATMENT FOR ADVANCED BREAST CANCER : THE GEICAM / GBG LEA STUDY (2012) (0)
The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy (2022) (0)
BCR-Induced VLA-4 Activation in the TCL1 Transgenic Mouse Model for Chronic Lymphocytic Leukemia (2019) (0)
OC-0476: Clinical results of triple negative breast cancer patients treated by IOERT-boost during breast conserving surgery (2015) (0)
A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (2013) (0)
Editorial Board (2011) (0)
Introduction to “Classic” Chronic Myeloproliferative Disorders (CMPDs) — Molecular and Cellular Biology (2010) (0)
Spliceosome Mediated RNA Trans-Splicing for Targeting Kappa+ B-Cell Neoplasms (2014) (0)
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer (2022) (0)
Chemotherapie im Alter (2005) (0)
Oxaliplatin, irinotecan, and bevacizumab followed by docetaxel and bevacizumab in inoperable gastric cancer: First results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). (2011) (0)
Azacitidine Is Feasible and Safe in Patients with MDS and Co-Existing Plasma Cell Dysplasias (PCD) - Report on 9 Patients From the Austrian Azacitidine Registry (AAR) (2011) (0)
Editorial Board (2011) (0)
Editorial Board / Contents / Imprint / Guidelines (2014) (0)
Recommendations from the society for diagnosis and therapy of haematological and oncological diseases Breast Cancer in Women (2018) (0)
Correction (1982) (0)
Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation (2017) (0)
The Integrin Adaptor Kindlin-3 Is Important for Development and Retention of Marginal Zone B Cells (2020) (0)
Short title: Thalidomide-Dexamethasone versus MP in myeloma (2008) (0)
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial) (2018) (0)
Abstract P1-13-10: Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Stage 1 results of a phase II trial (AGMT MBC-6) (2016) (0)
Abstract PS1-41: Does complete surgical removal of metastases in oligometastatic breast cancer improve survival? A matched-pair analysis of the AGMT_MBC-registry (2021) (0)
Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1 (2018) (0)
Abstract P1-15-01: Effect of concomitant statin treatment in postmenopausal patients with hormone-receptor positive early-stage breast cancer receiving adjuvant denosumab or placebo: A post-hoc analysis of ABCSG-18 (2022) (0)
Abstract P2-09-09: Polyligand profiling differentiates cancer patients according to their benefit of treatment (2018) (0)
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry (2021) (0)
Complete remission of disseminated Langerhans cell sarcoma after stem cell transplantation (2020) (0)
PF294 IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY (2019) (0)
Editorial Board / Impressum (2010) (0)
ASCO-update: gastrointestinal tumors (2017) (0)
T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies (2022) (0)
0156 Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial (2009) (0)
Editorial Board (2011) (0)
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes (2018) (0)
A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results. (2019) (0)
Contents, Vol. 107, 1995 (1995) (0)
but not motility, of chronic lymphocytic leukemia cells Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, (2014) (0)
2130 Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab + FOLFIRI (2015) (0)
Primary surgery versus no surgery in synchronous metastastic breast cancer: Patient-reported outcomes of the ABCSG 28 Posytive trial. (2017) (0)
mantle cell lymphoma 435 APOPTOSIS-RELATED GENES IDENTIFY POOR SURVIVAL GROUP AMONG MANTLE CELL LYMPHOMA PATIENTS (2008) (0)
Breast Care (2010) (0)
Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes due to reduced LFA-1 expression (2008) (0)
Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy (2019) (0)
Abstract P1-08-32: Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer (2013) (0)
The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms (2021) (0)
1530P Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis (2020) (0)
Abstract P6-08-47: Androgen receptor expression in pre-menopausal early breast cancer patients treated with endocrine therapy within the ABCSG-12 trial - a single center pilot analysis (2015) (0)
S819 PET AFTER 2 CYCLES OF ABVD IN PATIENTS WITH EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITHIN THE PHASE 3 GHSG HD16 STUDY (2019) (0)
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard Greil?

Richard Greil is affiliated with the following schools:

University of California, Los Angeles
Paracelsus Medical University
University of Salzburg
Masaryk University
University of Manchester
Karolinska Institute
Medical University of Graz
University of Innsbruck
Medical University of Vienna
Normandy University Group
University of Cologne
University of Pavia